Adial Pharmaceuticals reports Q1 results

1 month ago 5

Adial Pharmaceuticals press release (NASDAQ:ADIL): Q1 net Loss of $2.2 million.
Cash and cash equivalents were $2.4 million as of March 31, 2025, compared to $3.8 million as of December 31, 2024. Including the proceeds from the warrant exercises, the Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025 based on currently committed development plans.

Recommended For You